Recruitment Begins in Phase 1 Trial of C-CAR088 for Multiple Myeloma
A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study Cellular Biomedicine…
News
CLR 131 Significantly Extends Survival of Heavily Treated Multiple Myeloma Patients in Phase 1 Trial
Heavily treated multiple myeloma patients included in the first four dosing groups of Cellectar Biosciences’ Phase 1 trial lived for a median of 22 months…
Ayala Partnering with Novartis on Investigational AL102 for Treatment of Multiple Myeloma
In a new agreement, Ayala Pharmaceuticals will work with Novartis on the development and commercialization of AL102, an investigational treatment for…
Revlimid Maintenance Extends Survival Without Disease Worsening in Myeloma Patients, Phase 3 Trial Shows
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy…
First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis
A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first…
Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants
A study is recruiting participants to examine the molecular changes that occur when precursor conditions develop into full-blown multiple myeloma, information that can then be…
Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan
Janssen Pharmaceutical has submitted an application to Japanese authorities requesting that Darzalex (daratumumab) be approved, in combination with standard therapy, to treat newly diagnosed multiple myeloma patients…
Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients
The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive…
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to…
Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows
Early treatment with a triple combination therapy containing Empliciti (elotuzumab), Revlimid (lenalidomide), and dexamethasone in patients with smoldering multiple myeloma — a precursor of…
